DK3372683T3 - Fremgangsmåde til tilvejebringelse af tumorspecifikke t-celler og anvendelsen deraf - Google Patents
Fremgangsmåde til tilvejebringelse af tumorspecifikke t-celler og anvendelsen deraf Download PDFInfo
- Publication number
- DK3372683T3 DK3372683T3 DK18167345.0T DK18167345T DK3372683T3 DK 3372683 T3 DK3372683 T3 DK 3372683T3 DK 18167345 T DK18167345 T DK 18167345T DK 3372683 T3 DK3372683 T3 DK 3372683T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- procedure
- specific
- providing tumor
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180383 | 2015-08-10 | ||
| EP15202419 | 2015-12-23 | ||
| EP16753630.9A EP3180433B1 (en) | 2015-08-10 | 2016-08-10 | Method for providing tumour-specific t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3372683T3 true DK3372683T3 (da) | 2020-07-27 |
Family
ID=56738102
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18167345.0T DK3372683T3 (da) | 2015-08-10 | 2016-08-10 | Fremgangsmåde til tilvejebringelse af tumorspecifikke t-celler og anvendelsen deraf |
| DK16753630.9T DK3180433T3 (en) | 2015-08-10 | 2016-08-10 | Method for providing tumor-specific T cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16753630.9T DK3180433T3 (en) | 2015-08-10 | 2016-08-10 | Method for providing tumor-specific T cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190255162A1 (enExample) |
| EP (2) | EP3180433B1 (enExample) |
| JP (1) | JP6815400B2 (enExample) |
| DK (2) | DK3372683T3 (enExample) |
| ES (2) | ES2679798T3 (enExample) |
| WO (1) | WO2017025564A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908678A1 (en) * | 2019-01-10 | 2021-11-17 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
| EP4249592A3 (en) | 2021-07-15 | 2024-03-20 | Boehringer Ingelheim International GmbH | Identification of common tumor-specific t cell receptors and antigens |
| AU2022382915A1 (en) * | 2021-11-03 | 2024-05-16 | University Of Delaware | Cell-derived microparticle delivery system and uses thereof |
| CN114530202A (zh) * | 2021-12-20 | 2022-05-24 | 深圳泛因医学有限公司 | 鉴定抗原特异性tcr或bcr的方法及应用 |
| US20250368717A1 (en) | 2022-05-30 | 2025-12-04 | Hs Diagnomics Gmbh | Common tumor-specific t cell receptors |
| EP4649952A1 (en) | 2024-05-14 | 2025-11-19 | HS Diagnomics GmbH | Kras q16h specific t cell receptors and uses thereof |
| WO2025238079A1 (en) | 2024-05-14 | 2025-11-20 | Hs Diagnomics Gmbh | Kras q16h specific t cell receptors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0128153D0 (en) * | 2001-11-23 | 2002-01-16 | Bayer Ag | Profiling of the immune gene repertoire |
| DE102004063339A1 (de) | 2004-12-23 | 2006-07-06 | Bayer Technology Services Gmbh | Sonde zum Nachweis von Nukleinsäuren |
| EP2653556B1 (en) * | 2012-04-20 | 2015-09-02 | Alacris Theranostics GmbH | CDR sequence-specific enrichment of live immune cells |
| EP2746405B1 (en) | 2012-12-23 | 2015-11-04 | HS Diagnomics GmbH | Methods and primer sets for high throughput PCR sequencing |
| US11203783B2 (en) * | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
-
2016
- 2016-08-10 EP EP16753630.9A patent/EP3180433B1/en active Active
- 2016-08-10 DK DK18167345.0T patent/DK3372683T3/da active
- 2016-08-10 WO PCT/EP2016/069041 patent/WO2017025564A1/en not_active Ceased
- 2016-08-10 ES ES16753630.9T patent/ES2679798T3/es active Active
- 2016-08-10 US US15/751,883 patent/US20190255162A1/en not_active Abandoned
- 2016-08-10 EP EP18167345.0A patent/EP3372683B1/en active Active
- 2016-08-10 DK DK16753630.9T patent/DK3180433T3/en active
- 2016-08-10 JP JP2018527008A patent/JP6815400B2/ja active Active
- 2016-08-10 ES ES18167345T patent/ES2807026T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3180433B1 (en) | 2018-04-18 |
| EP3180433A1 (en) | 2017-06-21 |
| JP2018525034A (ja) | 2018-09-06 |
| DK3180433T3 (en) | 2018-07-30 |
| WO2017025564A1 (en) | 2017-02-16 |
| ES2807026T3 (es) | 2021-02-19 |
| CA3030959A1 (en) | 2017-02-16 |
| JP6815400B2 (ja) | 2021-01-20 |
| ES2679798T3 (es) | 2018-08-31 |
| EP3372683B1 (en) | 2020-05-27 |
| US20190255162A1 (en) | 2019-08-22 |
| EP3372683A1 (en) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| DK3390444T3 (da) | Anti-tl1a-antigenbindende proteiner og anvendelser deraf | |
| DK3922645T3 (da) | Anti-pro/latent-myostatin-antistoffer og anvendelse heraf | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3316909T5 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
| DK3264955T3 (da) | Blandeanordning og fremgangsmåde | |
| DK3430038T3 (da) | Sammensætninger og fremgangsmåder til cd20-immunterapi | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3224603T3 (da) | Nordning og fremgangsmåde til materialekarakteristik | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| DK3129779T3 (da) | Fremgangsmåder og sammensætninger til påvisning af fejlfoldede proteiner | |
| DK4293009T3 (da) | Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3372683T3 (da) | Fremgangsmåde til tilvejebringelse af tumorspecifikke t-celler og anvendelsen deraf | |
| DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol |